首頁 > 市場調查報告書 > 醫療設備

體外診斷癌症癌症診斷

市場調查報告書

商品編碼

1654724

全球肺癌診斷市場 - 2025 - 2033

Global Lung Cancer Diagnostics Market - 2025-2033

出版日期: 2025年02月13日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球肺癌診斷市場規模達 49.4 億美元，預計到 2033 年將達到 84.4 億美元，2025-2033 年預測期內的複合年成長率為 6.18%。

肺癌診斷對於肺癌的早期發現、準確診斷和有效治療至關重要，肺癌仍然是全球癌症相關死亡的主要原因之一。早期發現肺癌對於確定最佳治療方案和提高存活率至關重要。使用了多種診斷方法，包括 CT 掃描、X 光和 PET 掃描等影像技術，以及生物標記測試和基因分析。

液體活體組織切片是一種較新的非侵入性技術，因識別癌症的基因突變和特定特徵而越來越受歡迎。這些進步使得制定更個人化的治療方案成為可能，例如標靶治療或免疫療法，這些方案在改善患者預後方面顯示出良好的效果。

市場動態：

促進因素與約束因素

肺癌發生率上升

肺癌發生率的上升是推動肺癌診斷市場成長的關鍵因素。隨著全球病例數量持續增加，對有效和早期檢測方法的需求也越來越大。肺癌仍然是最致命和最常見的癌症之一，主要是由於吸煙、空氣污染和其他環境影響等因素造成的。

隨著每年被診斷出罹患癌症的人數越來越多，對更早、更容易治療的先進診斷工具的需求也顯著成長。例如，根據美國癌症協會的數據，預計 2025 年將報告約 226,650 例新的肺癌病例。一般來說，SCLC約佔所有肺癌病例的13%，而NSCLC約佔87%。

隨著肺癌病例數量的增加，醫療保健提供者和患者都在尋求更準確、更有效、更方便的診斷方法，以提高存活率。早期發現對於獲得更好的結果至關重要，對低劑量 CT 掃描和生物標記測試等篩檢工具的需求也日益增加。因此，肺癌病例數的增加是肺癌診斷市場發展的主要驅動力。

診斷測試費用高昂

診斷測試的高成本限制了人們獲得先進技術的管道，尤其是在中低收入地區，這對肺癌診斷市場的成長構成了重大挑戰。昂貴的診斷方法，例如液體活體組織切片、基因組檢測和 PET 掃描，對於許多患者來說往往是經濟上無法承受的，從而導致診斷延遲或依賴不太精確、更便宜的替代方法。

Lung cancer diagnostics are crucial for early detection, accurate diagnosis, and effective treatment of lung cancer, which remains one of the leading causes of cancer-related deaths worldwide. Detecting lung cancer early is vital for determining the best course of treatment and improving survival rates. A variety of diagnostic methods are used, including imaging techniques like CT scans, X-rays, and PET scans, as well as biomarker testing and genetic analysis.

Liquid biopsy, a newer and non-invasive technology, is also gaining popularity for identifying genetic mutations and specific characteristics of the cancer. These advancements have made it possible to create more personalized treatment plans, such as targeted therapies or immunotherapies, which are showing promising results in improving patient outcomes.

Market Dynamics: Drivers & Restraints

Rising incidence of lung cancer cases

The rising incidence of lung cancer is a key factor driving the growth of the lung cancer diagnostics market. As the number of cases continues to increase worldwide, there's a greater need for effective and early detection methods. Lung cancer remains one of the deadliest and most common cancers, largely due to factors like smoking, air pollution, and other environmental influences.

With more people being diagnosed each year, the demand for advanced diagnostic tools to catch the disease at an earlier, more treatable stage has grown significantly. For instance, according to the American Cancer Society, it is estimated that about 226,650 new cases of lung cancer cases are expected to report in 2025. Lung cancer statistics typically encompass both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Generally, SCLC accounts for about 13% of all lung cancer cases, while NSCLC makes up approximately 87%.

As the number of lung cancer cases rises, both healthcare providers and patients are looking for more accurate, efficient, and accessible diagnostic options to improve survival rates. Early detection is essential for better outcomes, and there's an increasing need for screening tools like low-dose CT scans and biomarker testing. Thus, the growing number of lung cancer cases is a major driver for the lung cancer diagnostics market.

High Costs of Diagnostic Tests

The high cost of diagnostic tests poses a significant challenge to the growth of the lung cancer diagnostics market by restricting access to advanced technologies, especially in low- and middle-income regions. Expensive diagnostic methods, such as liquid biopsies, genomic testing, and PET scans, are often financially inaccessible to many patients, resulting in delayed diagnoses or reliance on less precise, more affordable alternatives.

Segment Analysis

The global lung cancer diagnostics market is segmented based on cancer type, diagnostic test type, product type, end-user, and region.

Treatment:

Biopsy segment is expected to dominate the global lung cancer diagnostics market share

The biopsy segment is expected to lead the lung cancer diagnostics market because it plays a vital role in accurately diagnosing lung cancer. Methods like needle biopsies, bronchoscopic biopsies, and surgical biopsies are essential for confirming the presence of cancer cells and determining the type and stage of the disease. Different biopsy tests are introduced by the companies to enhance the accuracy of the diagnostic procedures. For instance, in October 2023, Delfi Diagnostics introduced its first liquid biopsy test, fulfilling the company's long-standing goal of providing a blood-based screening tool for lung cancer. The Firstlook Lung test aims to offer a more accessible and convenient detection method, reaching a broader population compared to current standards.

Recent advancements in minimally invasive techniques, such as CT-guided needle biopsies and EBUS-guided biopsies, have made it easier to collect tissue samples with fewer risks, which has led to wider adoption in clinical practice. Companies are forming partnerships to widen the usage pof the existing tests and products. For instance, in January 2023, Agilent and Quest Diagnostics have partnered to broaden access to the Agilent Resolution ctDx FIRST liquid biopsy next-generation sequencing (NGS) test. This FDA-approved, single-site premarket test serves as a companion diagnostic (CDx) to identify patients with advanced non-small cell lung cancer (NSCLC) who may benefit from treatment with adagrasib (brand name Krazati).

As precision medicine continues to gain importance, biopsies are key for genomic profiling and identifying biomarkers, which are crucial for selecting the most effective targeted therapies and immunotherapies. This ability to support personalized treatment is a major factor driving the dominance of the biopsy segment in the market.

Geographical Analysis

North America is expected to hold a significant position in the global lung cancer diagnostics market share

North America is expected to maintain a dominant position in the global lung cancer diagnostics market, driven by its advanced healthcare infrastructure and high lung cancer incidence. The region's access to cutting-edge diagnostic technologies, such as advanced imaging systems, liquid biopsies, and genomic testing, enables early and accurate detection of lung cancer, which is crucial for improving patient outcomes.

Growing awareness about the importance of early lung cancer screening, along with a rising emphasis on precision medicine, has fuelled the demand for effective and personalized diagnostic solutions. Moreover, the significant investments in healthcare research for diagnostic procedures, ensure that patients have greater access to the latest diagnostic tools. For instance, in October 2023, DELFI Diagnostics, Inc., a company focused on accessible blood-based tests to improve cancer detection, has announced the initial commercial launch of FirstLook Lung. This blood test provides a convenient, accurate, and personalized result by assessing the likelihood of detecting lung cancer through low-dose CT (LDCT), boasting an impressive negative predictive value (NPV) of 99.7%. These factors hold the region in the dominant position in the lung cancer diagnostics market.

Competitive Landscape

The major global players in the lung cancer diagnostics market include Quest Diagnostics Incorporated, Biodesix, Lepu Medical Technology (Beijing)Co., Ltd., DSS Imagetec, Abbott, Guardant Health, Intuitive Surgical, bioAffinity Technologies, Inc., Optellum Ltd and F. Hoffmann-La Roche Ltd. among others.

Key Developments

In January 2025, Monitor Corporation has begun selling its lung cancer diagnosis software in Japan through a partnership with Doctor-NET, a Japanese digital healthcare provider.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Lung Cancer Diagnostics Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Cancer Type
3.2. Snippet by Diagnostic Test Type
3.3. Snippet by Product Type
3.4. Snippet by End-User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising incidence of lung cancer cases
- 4.1.2. Restraints
  - 4.1.2.1. High Costs of Treatment
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs

6. By Cancer Type

6.1. Introduction
- 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 6.1.2. Market Attractiveness Index, By Cancer Type
6.2. Non-small Cell Lung Cancer*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Small Cell Lung Cancer

7. By Diagnostic Test Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
- 7.1.2. Market Attractiveness Index, By Diagnostic Test Type
7.2. Biopsies*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Imaging Tests
7.4. Molecular Testing
7.5. Others

8. By Product Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 8.1.2. Market Attractiveness Index, By Product Type
8.2. Instruments*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Consumables

9. By End-User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Diagnostic Centers
9.4. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.7.1. U.S.
  - 10.2.7.2. Canada
  - 10.2.7.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.7.1. Germany
  - 10.3.7.2. U.K.
  - 10.3.7.3. France
  - 10.3.7.4. Spain
  - 10.3.7.5. Italy
  - 10.3.7.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.7.1. Brazil
  - 10.4.7.2. Argentina
  - 10.4.7.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.7.1. China
  - 10.5.7.2. India
  - 10.5.7.3. Japan
  - 10.5.7.4. South Korea
  - 10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnostic Test Type
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

12.1. F. Hoffmann-La Roche Ltd*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio
  - 12.1.2.1. Product Description
  - 12.1.2.2. Product Key Performance Indicators (KPIs)
  - 12.1.2.3. Historic and Forecasted Product Sales
  - 12.1.2.4. Product Sales Volume
- 12.1.3. Financial Overview
  - 12.1.3.1. Company Revenue's
  - 12.1.3.2. Geographical Revenue Shares
  - 12.1.3.3. Revenue Forecasts
- 12.1.4. Key Developments
  - 12.1.4.1. Mergers & Acquisitions
  - 12.1.4.2. Key Product Development Activities
  - 12.1.4.3. Regulatory Approvals etc.
- 12.1.5. SWOT Analysis
12.2. Biodesix
12.3. Lepu Medical Technology (Beijing)Co., Ltd.
12.4. DSS Imagetec
12.5. Abbott
12.6. Guardant Health
12.7. Intuitive Surgical
12.8. bioAffinity Technologies, Inc.
12.9. Optellum Ltd
12.10. F. Hoffmann-La Roche Ltd.
Similar data will be provided for each market player.